| 1 |
Increased Expression of AKT3 in Neuroendocrine Differentiated Prostate Cancer Cells Alters the Response Towards Anti-Androgen Treatment |
|
|
| Marc Wiesehöfer,Elena Dilara Czyrnik,Martin Spahn,Saskia Ting,Henning Reis,Jaroslaw Thomas Dankert,Gunther Wennemuth |
|
| Cancers. 2021; 13(3): 578 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation |
|
|
| Havva Mehralitabar,A.S. Ghasemi,Jahed Gholizadeh |
|
| Steroids. 2021; : 108799 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Tissue engineered scaffolds as 3D models for prostate cancer metastasis to the bone |
|
|
| Simrit Safarulla,Pritisha S. Khillar,Sudarshan Kini,Amit Kumar Jaiswal |
|
| Materials Today Communications. 2021; : 102641 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Electrolyte Disorders Induced by Antineoplastic Drugs |
|
|
| Ignazio Verzicco,Giuseppe Regolisti,Federico Quaini,Pietro Bocchi,Irene Brusasco,Massimiliano Ferrari,Giovanni Passeri,Valentina Cannone,Pietro Coghi,Enrico Fiaccadori,Alessandro Vignali,Riccardo Volpi,Aderville Cabassi |
|
| Frontiers in Oncology. 2020; 10 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer |
|
|
| Nirmish Singla,Rashed A. Ghandour,Ganesh V. Raj |
|
| Expert Opinion on Investigational Drugs. 2019; 28(3): 249 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial |
|
|
| Matthew Smith,Chris Parker,Fred Saad,Kurt Miller,Bertrand Tombal,Quan Sing Ng,Martin Boegemann,Vsevolod Matveev,Josep Maria Piulats,Luis Eduardo Zucca,Oleg Karyakin,Go Kimura,Nobuaki Matsubara,William Carlos Nahas,Franco Nolč,Eli Rosenbaum,Axel Heidenreich,Yoshiyuki Kakehi,Amily Zhang,Heiko Krissel,Michael Teufel,Junwu Shen,Volker Wagner,Celestia Higano |
|
| The Lancet Oncology. 2019; 20(3): 408 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group |
|
|
| Joe M. OćSullivan,Joan Carles,Richard Cathomas,Alfonso Gomez-Iturriaga,Daniel Heinrich,Gero Kramer,Piet Ost,Inge van Oort,Bertrand Tombal |
|
| European Urology Oncology. 2019; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA) |
|
|
| Yogita Patil,Hilary Shmeeda,Yasmine Amitay,Patricia Ohana,Saran Kumar,Alberto Gabizon |
|
| Nanomedicine: Nanotechnology, Biology and Medicine. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate |
|
|
| Tamás Solymosi,Ferenc Tóth,János Orosz,Orsolya Basa-Dénes,Réka Angi,Tamás Jordán,Zsolt Ötvös,Hristos Glavinas |
|
| Journal of Chemical & Engineering Data. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
Human cytochrome P450 enzymes 5–51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition – toxic effects and benefits |
|
|
| Slobodan P. Rendic,F. Peter Guengerich |
|
| Drug Metabolism Reviews. 2018; 50(3): 256 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay |
|
|
| Joseph Shaw,Mathew Leveridge,Charlotta Norling,Jakob Karén,Daniel Martinez Molina,Daniel O’Neill,James E. Dowling,Paul Davey,Suzanna Cowan,Michael Dabrowski,Martin Main,Davide Gianni |
|
| Scientific Reports. 2018; 8(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics |
|
|
| Charles F. Polotti,Christopher J. Kim,Nadiya Chuchvara,Alyssa B. Polotti,Eric A. Singer,Sammy Elsamra |
|
| Expert Opinion on Drug Metabolism & Toxicology. 2017; 13(12): 1265 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer |
|
|
| D. S. Mikhaylenko,G. D. Efremov,A. V. Sivkov,D. V. Zaletaev |
|
| Molecular Biology. 2016; 50(1): 28 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature |
|
|
| Ian M. Bird,David H. Abbott |
|
| The Journal of Steroid Biochemistry and Molecular Biology. 2016; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 15 |
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential |
|
|
| Anitha B. Alex,Sumanta K. Pal,Neeraj Agarwal |
|
| Therapeutic Advances in Medical Oncology. 2016; 8(4): 267 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 16 |
First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN) |
|
|
| Mikhail Paltsev,Vsevolod Kiselev,Vadim Drukh,Ekaterina Muyzhnek,Igor Kuznetsov,Evgeniya Andrianova,Pavel Baranovskiy |
|
| EPMA Journal. 2016; 7(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 17 |
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis |
|
|
| Sameer S. Udhane,Bernhard Dick,Qingzhong Hu,Rolf W. Hartmann,Amit V. Pandey |
|
| Biochemical and Biophysical Research Communications. 2016; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 18 |
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review |
|
|
| Archana Anantharaman,Terence W. Friedlander |
|
| Urologic Oncology: Seminars and Original Investigations. 2015; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 19 |
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer |
|
|
| Christopher Sejong Han,Rutveej Patel,Isaac Yi Kim |
|
| Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(6): 967 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 20 |
Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1) |
|
|
| Richard L Schroeder,Phan Tram,Jiawang Liu,Maryam Foroozesh,Jayalakshmi Sridhar |
|
| Expert Opinion on Therapeutic Patents. 2015; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 21 |
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells |
|
|
| Lingling Fan,Guihong Peng,Arif Hussain,Ladan Fazli,Emma Guns,Martin Gleave,Jianfei Qi |
|
| Journal of Biological Chemistry. 2015; 290(34): 20865 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 22 |
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review) |
|
|
| BJÖRN GEORGI,NINA KORZENIEWSKI,BORIS HADASCHIK,CARSTEN GRÜLLICH,WILFRIED ROTH,HOLGER SÜLTMANN,SASCHA PAHERNIK,MARKUS HOHENFELLNER,STEFAN DUENSING |
|
| International Journal of Oncology. 2014; 45(4): 1337 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
